199 related articles for article (PubMed ID: 30579358)
1. Episcleritis in a patient with mucosal melanoma treated with interferon alfa-2b and radiotherapy: a case report.
Yang L; Ji S; Wang L; Zhang Y
J Med Case Rep; 2018 Dec; 12(1):388. PubMed ID: 30579358
[TBL] [Abstract][Full Text] [Related]
2. Resolution of conjunctival melanoma with topical interferon alpha 2b in a patient with mitomycin C intolerance.
Chaparro Tapias TA; Díaz Díaz AL; Secondi R; Coy Villamil H; Sánchez España JC
Arch Soc Esp Oftalmol (Engl Ed); 2018 Nov; 93(11):558-561. PubMed ID: 30072188
[TBL] [Abstract][Full Text] [Related]
3. Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex.
Finger PT; Sedeek RW; Chin KJ
Am J Ophthalmol; 2008 Jan; 145(1):124-129. PubMed ID: 17981257
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment outcomes and prognosis of mucosal melanoma of the head and neck: 161 cases from a single institution.
Sun S; Huang X; Gao L; Zhang Y; Luo J; Zhang S; Wang K; Qu Y; Wu R; Liu Q; Xiao J; Xu G; Yi J
Oral Oncol; 2017 Nov; 74():115-122. PubMed ID: 29103739
[TBL] [Abstract][Full Text] [Related]
5. Treatment of conjunctival and corneal epithelial neoplasia with retinoic acid and topical interferon alfa-2b: long-term follow-up.
Krilis M; Tsang H; Coroneo M
Ophthalmology; 2012 Oct; 119(10):1969-73. PubMed ID: 22704834
[TBL] [Abstract][Full Text] [Related]
6. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis.
Lane AM; Egan KM; Harmon D; Holbrook A; Munzenrider JE; Gragoudas ES
Ophthalmology; 2009 Nov; 116(11):2206-12. PubMed ID: 19744725
[TBL] [Abstract][Full Text] [Related]
8. Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma.
Wong SF; Jakowatz JG; Taheri R
Clin Ther; 2005 Dec; 27(12):1942-8. PubMed ID: 16507380
[TBL] [Abstract][Full Text] [Related]
9. Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies.
Kirkwood JM
Eur J Cancer; 1998 Jul; 34 Suppl 3():S12-7. PubMed ID: 9849403
[TBL] [Abstract][Full Text] [Related]
10. An update on the current management of head and neck mucosal melanoma.
Green B; Elhamshary A; Gomez R; Rahimi S; Brennan PA
J Oral Pathol Med; 2017 Aug; 46(7):475-479. PubMed ID: 27864904
[TBL] [Abstract][Full Text] [Related]
11. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of conjunctival melanoma treated with topical interferon alpha-2b eye drops as adjunctive therapy following surgical resection.
Kikuchi I; Kase S; Ishijima K; Ishida S
Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2271-2276. PubMed ID: 28752368
[TBL] [Abstract][Full Text] [Related]
13. Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.
Bramlette TB; Lawson DH; Washington CV; Veledar E; Johns BR; Brisman SF; Abramova L; Chen SC
Dermatol Surg; 2007 Jan; 33(1):11-6. PubMed ID: 17214673
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.
Jonasch E; Kumar UN; Linette GP; Hodi FS; Soiffer RJ; Ryan BF; Sober AJ; Mihm MC; Tsao H; Langley RG; Cosimi BA; Gadd MA; Tanabe KK; Souba W; Haynes HA; Barnhill R; Osteen R; Haluska FG
Cancer J; 2000; 6(3):139-45. PubMed ID: 10882328
[TBL] [Abstract][Full Text] [Related]
15. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study.
Dithmar S; Rusciano D; Lynn MJ; Lawson DH; Armstrong CA; Grossniklaus HE
Arch Ophthalmol; 2000 Aug; 118(8):1085-9. PubMed ID: 10922203
[TBL] [Abstract][Full Text] [Related]
17. Multidisciplinary Approach for Management of a Patient with Oral Mucosal Malignant Melanoma.
Eachempati P; Aggarwal H; Shenoy VK; Baliga M
J Coll Physicians Surg Pak; 2018 Sep; 28(9):S187-S189. PubMed ID: 30173693
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced hepatitis in a patient with malignant melanoma treated with interferon alfa 2b adjuvantly who had been administered gemfibrozil in therapy.
Grubisić-Cabo F; Vrdoljak E
Med Oncol; 2006; 23(1):121-4. PubMed ID: 16645237
[TBL] [Abstract][Full Text] [Related]
19. [Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma].
Richtig E; Langmann G; Schlemmer G; Müllner K; Papaefthymiou G; Bergthaler P; Smolle J
Ophthalmologe; 2006 Jun; 103(6):506-11. PubMed ID: 16763868
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
